Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.71 |
| ▸ | CCR8 | P51685 | 1/20 | 0.71 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.45 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3389045 | 0.85 | CCR1 (0.58) | CCR1CCR8CYP2A6METAP2NOS3 | |
| SCHEMBL29388304 | 0.84 | CCR1 (1.00) | CCR1CCR8CYP2A6METAP2NOS3 | |
| SCHEMBL196966 | 0.84 | CCR1 (1.00) | CCR1CCR8CYP2A6METAP2NOS3 | |
| SCHEMBL30511194 | 0.84 | CCR1 (1.00) | CCR1CCR8CYP2A6METAP2NOS3 | |
| SCHEMBL20557390 | 0.81 | CCR1 (0.94) | CCR1CCR8CYP2A6METAP2NOS3 | |
| SCHEMBL3422291 | 0.81 | CCR1 (0.94) | CCR1CCR8CYP2A6METAP2NOS3 | |
| SCHEMBL29751919 | 0.81 | CCR1 (0.94) | CCR1CCR8CYP2A6METAP2NOS3 | |
| SCHEMBL29751933 | 0.81 | CCR1 (0.94) | CCR1CCR8CYP2A6METAP2NOS3 | |
| SCHEMBL3423401 | 0.81 | CCR1 (0.94) | CCR1CCR8CYP2A6METAP2NOS3 | |
| SCHEMBL3409467 | 0.81 | CCR1 (0.65) | CCR1CCR8CYP2A6METAP2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036418-A1 | Pharmaceutical composition for treatment of cancer containing pyridylpyridazine or transition metal complex thereof as active ingredient | INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY, THE (KR) | 2009-02-05 | — | — | US | disclosed |
| WO-2007007943-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OF CANCER COMPRISING PYRIDYLPYRIDAZINE COMPOUNDS OR THEIR TRANSITION METAL COMPLEXES | THE INDUSTRY AND ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC) (KR) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036418-A1 | Pharmaceutical composition for treatment of cancer containing pyridylpyridazine or transition metal complex thereof as active ingredient | CA5A, PDCD11, PDCD1 | CCR1 3412/4885CCR8 3050/4885CYP2A6 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.